EUVIMEDEUVIMED entdecken
Open Access

Clinical Actionability of the NUDT15 * 4 (p. R139H ) Allele and Its Association With Hispanic Ethnicity

Maud Maillard iD, Jenny Q Nguyen iD, Wenjian Yang iD, Keito Hoshitsuki iD, Mary V Relling iD, Kelly E Caudle iD, Kristine R Crews iD, Sima Jeha iD, Hiroto Inaba iD, Ching-Hon Pui iD, Smita Bhatia iD, Seth E Karol iD und 4 weitere

Clinical Pharmacology & Therapeutics · 2025

DOI: 10.1002/cpt.3501 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, 2025. Verfasst von Maud Maillard und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA. Hauptthemen laut MEDLINE: Pyrophosphatases, Hispanic or Latino, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Mercaptopurine. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, American Lebanese Syrian Associated Charities, National Institutes of Health (NIH).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nudix hydrolase 15 (NUDT15) deficiency is strongly associated with thiopurine‐induced myelosuppression. Currently, testing for NUDT15 deficiency is based on the genotyping of the most frequent and clinically characterized no‐function variants, that is, * 2 , * 3 and * 9 . The Hispanic/Latino‐predominant variant NUDT15 * 4 (p.R139H) is classified as “uncertain function” by the Clinical Pharmacogenetics Implementation Consortium, because of insufficient data to ascertain its clinical actionability. In this study, we evaluated the association of NUDT15 * 4 with mercaptopurine (6‐MP) tolerance in a retrospective cohort of 1,399 patients with acute lymphoblastic leukemia (ALL) of diverse ancestries. All patients were wildtype for thiopurine methyltransferase gene. Patients were treated with 6‐MP in the context of ALL frontline clinical trials. The tolerated dose of 6‐MP was used to assess drug toxicity during the maintenance phase of ALL therapy. Patients with NUDT15 * 1 /* 4 ( n = 16, all of whom self‐identified as Hispanic/Latino) tolerated a significantly lower dose of 6‐MP than did those with NUDT15 * 1 /* 1 : median [interquartile range] of 39.0 [21.2–52.8] mg/m 2 , vs. 62.2 [47.9–71.6] mg/m 2 , P value < 0.001. No patient homozygous for * 4 was detected. In a separate retrospective validation study, six patients were identified as having NUDT15 * 1 /* 4 by routine clinical pharmacogenetics testing and tolerated a 6‐MP median dose of 38.7 mg/m 2 (IQR, 33.7–54.0), confirming the need for dose reduction attributed to the NUDT15 * 4 variant. These results point to the need to include NUDT15 * 4 in pharmacogenetics‐guided thiopurine dosing algorithms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyrophosphatasesHispanic or LatinoPrecursor Cell Lymphoblastic Leukemia-LymphomaMercaptopurineAntimetabolites, AntineoplasticHumansMaleFemaleRetrospective StudiesAdultMiddle AgedAllelesAdolescentYoung AdultChildGenotypeNudix Hydrolases

Substanzen

PyrophosphatasesNUDT15 protein, humanMercaptopurineAntimetabolites, AntineoplasticNudix Hydrolases

Autor:innen und Institutionen

  • Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
  • Personalized Care Program, Children's Hospital Los Angeles, Los Angeles, California, USA.
  • Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
  • Department of Global Pediatric Medicine, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
  • Division of Pediatric Hematology-Oncology, Institute for Cancer Outcomes and Survivorship, University of Alabama, Birmingham, Alabama, USA.
  • Unidad Nacional de Oncología Pediátrica, Marroquin University School of Medicine, Guatemala City, Guatemala.

ORCID-Profile: Maud Maillard, Jenny Q Nguyen, Wenjian Yang, Keito Hoshitsuki, Mary V Relling, Kelly E Caudle, Kristine R Crews, Sima Jeha, Hiroto Inaba, Ching-Hon Pui, Smita Bhatia, Seth E Karol, Federico G Antillon-Klussmann, Cyrine E Haidar, Deepa Bhojwani, Jun J Yang

Förderung

  • NCI NIH HHS
  • American Lebanese Syrian Associated Charities
  • National Institutes of Health (NIH)
  • Children's Oncology Group
  • NIGMS NIH HHS
  • Children’s Oncology Group

Zitieren

APA

Maillard, M., Nguyen, J. Q., Yang, W., Hoshitsuki, K., Relling, M. V., Caudle, K. E., Crews, K. R., Jeha, S., Inaba, H., Pui, C. H., Bhatia, S., Karol, S. E., Antillon-Klussmann, F. G., Haidar, C. E., Bhojwani, D., & Yang, J. J. (2025). Clinical Actionability of the NUDT15 * 4 (p. R139H ) Allele and Its Association With Hispanic Ethnicity. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3501

Vancouver

Maillard M, Nguyen JQ, Yang W, Hoshitsuki K, Relling MV, Caudle KE, et al. Clinical Actionability of the NUDT15 * 4 (p. R139H ) Allele and Its Association With Hispanic Ethnicity. Clinical Pharmacology & Therapeutics. 2025. doi:10.1002/cpt.3501

BibTeX
@article{Maillard2025,
  author = {Maillard, Maud and Nguyen, Jenny Q and Yang, Wenjian and Hoshitsuki, Keito and Relling, Mary V and Caudle, Kelly E and Crews, Kristine R and Jeha, Sima and Inaba, Hiroto and Pui, Ching-Hon and Bhatia, Smita and Karol, Seth E and Antillon-Klussmann, Federico G and Haidar, Cyrine E and Bhojwani, Deepa and Yang, Jun J},
  title = {Clinical Actionability of the NUDT15 * 4 (p. R139H ) Allele and Its Association With Hispanic Ethnicity},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2025},
  doi = {10.1002/cpt.3501}
}
Kostenlos starten →